Corticotropin-Releasing Hormone (CRH)
Also known as: CRH, CRF, corticotropin-releasing factor, corticoliberin, ovine CRH, human CRH
Endogenous hypothalamic neuropeptide; 41-amino acid peptide hormone; HPA axis regulator; diagnostic stimulation agent
What it is
Corticotropin-Releasing Hormone (CRH) is used clinically by endocrinologists to diagnose adrenal insufficiency, Cushing's syndrome, and pituitary tumors via stimulation testing. Researchers also study it in stress-related psychiatry, preterm birth prediction, and irritable bowel syndrome, given its central role in coordinating the body's stress response.
The scientific side
Corticotropin-Releasing Hormone is a 41-amino acid peptide synthesized and secreted primarily by parvocellular neurons of the hypothalamic paraventricular nucleus (PVN). Upon release into the hypothalamo-hypophyseal portal circulation, CRH binds to CRH receptor type 1 (CRH-R1), a G protein-coupled receptor expressed on corticotroph cells of the anterior pituitary, triggering adenylyl cyclase activation, cyclic AMP accumulation, and downstream protein kinase A signaling. This cascade stimulates synthesis and secretion of proopiomelanocortin (POMC)-derived peptides, most importantly adrenocorticotropic hormone (ACTH). ACTH then acts on the adrenal cortex to stimulate cortisol biosynthesis and secretion, completing the hypothalamic-pituitary-adrenal (HPA) axis activation loop. Glucocorticoids exert negative feedback at both the pituitary and hypothalamus to suppress CRH and ACTH release, forming a homeostatic regulatory circuit. CRH also acts through a second receptor subtype, CRH-R2, which is expressed in peripheral tissues including the heart, vasculature, skeletal muscle, and gastrointestinal tract, where it generally exerts vasodilatory and cardioprotective effects that are distinct from the stress-axis activation driven by CRH-R1. Beyond its neuroendocrine role, CRH functions as a central neuropeptide with direct anxiogenic and depressogenic effects mediated by CRH-R1 in limbic structures including the amygdala, hippocampus, and prefrontal cortex. Elevated CRH signaling in these brain regions drives autonomic arousal, increased heart rate via sympathotonic effects, behavioral fear responses, and HPA hyperactivation documented in major depressive disorder, post-traumatic stress disorder, and anxiety disorders. In the gastrointestinal tract, CRH acting via CRH-R1 on colonocytes activates cAMP/Ras/MAPK signaling, impairs mitochondrial function, disrupts epithelial barrier integrity, and alters gut microbiota composition — a mechanism proposed to underlie stress-induced gastrointestinal syndromes including diarrhea-predominant irritable bowel syndrome. Placental CRH, biosynthesized by syncytiotrophoblast cells during pregnancy, rises exponentially across gestation and has been proposed as a biological clock governing the timing of parturition; elevated mid-pregnancy placental CRH is associated with preterm birth risk. Clinically, exogenous ovine or human CRH administered intravenously produces a rapid, robust ACTH and cortisol surge in healthy individuals and in patients with pituitary-source Cushing's disease, but blunted or absent responses in patients with ectopic ACTH-secreting tumors or primary adrenal disease — the basis of CRH stimulation testing for Cushing's syndrome.
Class: Endogenous hypothalamic neuropeptide; 41-amino acid peptide hormone; HPA axis regulator; diagnostic stimulation agent
Administration & storage
- Administration
- Intravenous bolus injection (over 30–60 seconds via indwelling IV catheter)Slow intravenous infusion over 3–5 minutes in some research protocols
- Storage
- Lyophilized CRH powder should be stored at -20°C or colder and protected from light until reconstitution. Reconstituted solutions are not stable for prolonged storage and should be used within 2 hours of preparation. Do not freeze reconstituted solution.
- Cautions
- CRH is for clinical and research use only; self-administration by consumers is not established, is not supported by evidence, and carries significant risks including severe cardiovascular and endocrine effects,Transient facial flushing, warmth, or redness at the injection site occurs in the majority of patients receiving IV CRH bolus in clinical studies — typically mild and lasting less than 5 minutes,CRH bolus produces measurable increases in heart rate and sympathetic tone; use with caution in patients with known cardiovascular disease, arrhythmia, or severe hypertension,CRH administration in patients with primary adrenal insufficiency (Addison's disease) can trigger an exaggerated ACTH surge; adrenal insufficiency should be confirmed or excluded before unmonitored administration,No validated safety data exist for repeated, self-administered, or non-diagnostic use of CRH outside a monitored clinical setting,Ovine CRH (derived from sheep sequence) may theoretically carry immunogenic risk with repeated exposures, though no published anaphylaxis reports from standard single-dose testing were identified in reviewed literature
Legal & regulatory status
No exogenous CRH formulation is currently FDA-approved for therapeutic use. Ovine CRH (Acthrel, Ferring Pharmaceuticals) was previously FDA-approved as a diagnostic agent for stimulation testing in the differential…
CRH and its synthetic analogs are not explicitly named on the current WADA Prohibited List. Endogenous CRH itself has no documented ergogenic application in sport. However, any substance administered to manipulate the…
No therapeutic approval for exogenous CRH peptide has been identified in the reviewed literature for Health Canada. Ovine CRH for diagnostic stimulation testing may be available through Health Canada's Special Access…
What it's studied for
- Differential diagnosis of Cushing's syndrome via CRH stimulation testing Established clinical diagnostic use; systematic review and meta-analysis evidence; multiple prospective and retrospective cohort studies
- Evaluation of secondary adrenal insufficiency and HPA axis function Established clinical diagnostic use; retrospective cohort studies; Japanese endocrine guidelines-supported
- Identification of CRH-responsive somatotroph adenomas in acromegaly Retrospective comparative cohort study
- Stress-related psychiatric disorders — depression, anxiety, and PTSD (CRH receptor antagonist drug target validation) Phase I/II clinical trials; multiple prospective clinical studies; strong mechanistic evidence
- Preterm birth prediction and placental clock biology Prospective cohort studies; epidemiological studies; mechanistic evidence in human placenta
- Stress-induced gastrointestinal dysfunction and irritable bowel syndrome Human and preclinical mechanistic studies; clinical correlation studies
- Autonomic nervous system and cardiovascular effects of exogenous CRH Controlled human experimental study
- Infantile epileptic spasms syndrome — CRH-R1 as emerging therapeutic target Preclinical mechanistic evidence; early translational research
Safety signals
- Facial flushing, warmth, and transient skin erythema
- Transient heart rate increase and sympathetic activation
- Exaggerated ACTH and cortisol surge in patients with Cushing's disease
- Sympathetically mediated anxiety and behavioral arousal with high or repeated CRH exposure
- Gastrointestinal discomfort and potential gut barrier disruption with elevated or prolonged CRH exposure
- HPA axis suppression risk with CRH receptor antagonist co-administration (crinecerfont/CRHR1 antagonists)
- Placental CRH-mediated risk of preterm birth with early or excessive placental CRH activation
- Potential immunogenic reactions with repeated ovine CRH use in humans
No peer-reviewed studies indexed for this peptide yet.
Frequently asked
Is CRH available for self-injection to boost energy or stress resilience?
No. CRH is not available as an approved or commercially produced injectable for consumer use. The only clinical form — ovine CRH (Acthrel) — has been commercially discontinued in the US and is only used within hospitals under physician supervision for specific diagnostic tests. Self-administering CRH carries significant risks including cardiovascular stimulation, triggering of panic-like states, and dangerous HPA axis disruption. There is no evidence base for any wellness or performance application of CRH in humans.
What does the CRH stimulation test tell a doctor?
A CRH stimulation test involves a single intravenous injection of CRH and blood draws over the next hour to measure how much ACTH and cortisol your pituitary and adrenal glands produce. Doctors use it primarily to diagnose Cushing's syndrome (whether excess cortisol originates from a pituitary tumor, an adrenal tumor, or a tumor elsewhere in the body) and to evaluate whether the pituitary is the cause of adrenal insufficiency (low cortisol). The pattern of the ACTH and cortisol response helps pinpoint the source of the problem.
How does CRH relate to stress, anxiety, and depression?
CRH is your body's primary stress-initiating signal. When your brain perceives a threat, hypothalamic CRH is released first, triggering a cascade that ends in cortisol production by your adrenal glands. In people with chronic depression, anxiety, or PTSD, CRH is often overproduced in limbic brain regions, perpetuating a state of heightened arousal, fear, and HPA axis dysregulation. Researchers have studied drugs that block the CRH receptor (CRH-R1 antagonists) as potential antidepressants, with some early clinical evidence of benefit, though no such drug has yet been approved for psychiatric use.
What is the connection between CRH and preterm birth?
During pregnancy, the placenta — not just the brain — produces CRH. Placental CRH rises exponentially throughout pregnancy and is thought to act as a biological timer that signals when the body is ready for labor. Women who go into preterm labor often have elevated placental CRH levels earlier in pregnancy than women who deliver at term. Researchers are studying whether measuring CRH levels in pregnancy can help predict preterm birth risk, but no CRH-based preventive therapy for preterm birth is currently approved.
Why is CRH no longer available in the US for testing?
Ovine CRH (Acthrel) was commercially discontinued in the US due to manufacturer business decisions, not safety concerns. Because it was used in relatively small numbers of specialized diagnostic procedures each year, the commercial market was limited. Since its discontinuation, endocrinologists have largely shifted to desmopressin (DDAVP) as an alternative stimulating agent for inferior petrosal sinus sampling in Cushing's disease workup. Studies confirm desmopressin has somewhat lower diagnostic sensitivity than CRH for this purpose but is considered an acceptable alternative given availability constraints.
What is crinecerfont and how does it relate to CRH?
Crinecerfont (brand name Crenessity) is the first FDA-approved drug that works by blocking the CRH receptor type 1 (CRH-R1). Rather than mimicking CRH, it inhibits the receptor that CRH activates on pituitary cells. This reduces excess ACTH production in people with classic congenital adrenal hyperplasia (CAH), a genetic disorder causing dangerously high androgen levels. By lowering ACTH without removing all glucocorticoid replacement, crinecerfont allows people with CAH to take lower — safer — doses of cortisol-replacement steroids. It does not treat general stress, anxiety, or other CRH-related conditions at this time.